ME Therapeutics Holdings, Inc. (METX) Stock Statistics & Valuation Metrics

ME Therapeutics Holdings, Inc. has a market cap or net worth of C$59.80M. The enterprise value is C$117.03M.

ME Therapeutics Holdings, Inc. has 30,049,494 shares outstanding. The number of shares has decreased by -2.65% in one year.

ME Therapeutics Holdings, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of ME Therapeutics Holdings, Inc. is ―. ME Therapeutics Holdings, Inc.’s PEG ratio is ―.

In the last 12 months, ME Therapeutics Holdings, Inc. had revenue of ― and earned -1.29M in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

ME Therapeutics Holdings, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

ME Therapeutics Holdings, Inc. upcoming earnings date is Dec 2, 2026, After Close (Confirmed).

ME Therapeutics Holdings, Inc. as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, ME Therapeutics Holdings, Inc. has paid ― in taxes.

ME Therapeutics Holdings, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

ME Therapeutics Holdings, Inc. has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for ME Therapeutics Holdings, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―